Umbilical cord blood shot for low platelets after cancer treatment
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests an injection made from umbilical cord blood to raise low platelet counts caused by cancer therapies like chemo, immunotherapy, or radiation. It may help people with mild to moderate low platelets who haven't had recent platelet transfusions or other platelet-raising drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old
- You have a confirmed cancer diagnosis and your platelet count is between 50 and 100 (low but not dangerously low) due to cancer treatment
- You have not had a platelet transfusion or used platelet-raising drugs like Nplate or Promacta in the past week
- You are able to care for yourself (ECOG performance status 0, 1, or 2) and your life expectancy is over 3 months
- You do not have a bleeding disorder, history of blood clots, severe heart disease, or active serious infection
- If female and able to become pregnant, you agree to use effective birth control during the trial and for 6 months after, and have a negative pregnancy test before starting
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether umbilical cord blood can help raise platelet levels in people whose platelets drop after cancer treatment. If it works, it might reduce the need for platelet transfusions and lower bleeding risk.
This study tests an injection called MegaLT to help your body make platelets (blood cells that help stop bleeding) faster after a cord blood transplant. If you are recovering from a cord blood transplant for a blood cancer, this might help reduce the time you need platelet transfusions.
This trial studies how best to prevent and treat dangerous blood clots in people with cancer who also have very low platelets. It may help guide safer blood-thinner treatment when bleeding risk is high.
This trial tests whether umbilical cord mesenchymal stem cell exosomes can help restore blood cell counts after chemotherapy in adults with acute myeloid leukemia who are in remission. It aims to reduce the risk of infection and bleeding while waiting for bone marrow recovery.
This study tests whether umbilical cord blood cells can help people whose blood counts stay dangerously low after immune-based cancer treatments like CAR-T or bispecific antibodies. The treatment aims to boost your blood cell recovery and reduce the need for transfusions.
This Phase 2 study tests eltrombopag to help people with low platelet counts caused by chemotherapy (which can increase bleeding risk). It looks at whether raising platelets can reduce bleeding problems and help you stay on track with care.
Hear when a new Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.